Marché thérapeutique de la polyneuropathie démyélinisante inflammatoire chronique : l’approbation de la FDA pour Privigen® [Immunoglobuline intraveineuse (humaine), 10 % liquide] augmentera la croissance, selon Fortune Insights

Growing prevalence of ‘chronic inflammatory demyelinating polyneuropathy’ is driving the global chronic inflammatory demyelinating polyneuropathy therapy market (Others), by route of administration (oral, injectable), by distribution channel (hospital pharmacy, retail pharmacy , online pharmacy) and geographic forecast to 2026. Increasing R&D investments and strategic research collaborations between pharmaceutical industries are factors that are expected to enable the growth of the global chronic inflammatory demyelinating polyneuropathy therapeutics market.

Request a copy of the research report

www.fortunebusinessinsights.com/enquiry/sample/chronic-inflammatoire-demyelinating-polyneuropathy-therapeutics-market-100717

Rising prevalence of chronic inflammatory demyelinating polyneuropathy will allow growth in North America

Geographically, the global chronic inflammatory demyelinating polyneuropathy therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is projected to dominate the global Chronic Inflammatory Inflammatory Demyelinating Polyneuropathy Therapies market during the forecast period owing to the increasing prevalence of Chronic Inflammatory Inflammatory Demyelinating Polyneuropathy in the region. According to the CIDP Foundation International, chronic inflammatory demyelinating polyneuropathy (CIDP) affects approximately 8.9% per 100,000 people each year in North America. These factors together are expected to propel the growth of the global chronic inflammatory demyelinating polyneuropathy therapeutics market. North America. Europe followed by Asia-Pacific are expected to experience significant growth over the forecast period due to active government support. The developing healthcare infrastructure along with the growing focus by healthcare organizations and government on developing novel therapies for Chronic Inflammatory Demyelinating Polyneuropathy are also expected to contribute to the growth of the global Inflammatory Demyelinating Polyneuropathy Therapies market. chronicle in Asia-Pacific and Europe. Asia-Pacific is expected to experience significant growth during the forecast period due to active government support. The developing healthcare infrastructure along with the growing focus by healthcare organizations and government on developing novel therapies for Chronic Inflammatory Demyelinating Polyneuropathy are also expected to contribute to the growth of the global Inflammatory Demyelinating Polyneuropathy Therapies market. chronicle in Asia-Pacific and Europe. Asia-Pacific is expected to experience significant growth during the forecast period due to active government support. The developing healthcare infrastructure along with the growing focus by healthcare organizations and government on developing novel therapies for Chronic Inflammatory Demyelinating Polyneuropathy are also expected to contribute to the growth of the global Inflammatory Demyelinating Polyneuropathy Therapies market. chronicle in Asia-Pacific and Europe.

Certaines des principales entreprises présentes sur le marché mondial de la thérapie de la polyneuropathie inflammatoire démyélinisante chronique sont CSL Behring, ADMA Biologics, Grifols, SA, Shire, Pfizer Inc., GeNeuro SA, Gilead Sciences, Inc., Galapagos NV, Astellas Pharma, AbbVie , Inc., Mitsubishi Tanabe Pharma Corporation et autres.

Avez-vous une question ? Demandez à nos experts

www.fortunebusinessinsights.com/enquiry/speak-to-analyst/chronic-inflammatoire-demyelinating-polyneuropathy-therapeutics-market-100717

L’approbation de Privigen® par la FDA favorisera la croissance du marché

CSL Behring, un leader mondial de la biothérapie, a lancé Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] après avoir reçu l’approbation de la FDA. Le médicament sera utilisé pour le traitement des adultes atteints de polyneuropathie démyélinisante inflammatoire chronique (CIDP) afin d’améliorer le handicap neuromusculaire. Le lancement de Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] devrait contribuer aux revenus mondiaux du marché thérapeutique de la polyneuropathie inflammatoire démyélinisante inflammatoire chronique, car la thérapie qui améliore et maintient la force et la fonction tout en prévenant les rechutes et en minimisant le côté effets. En outre, le lancement des essais cliniques de phase 2 pour le rozanolixizumab est également susceptible de stimuler la croissance mondiale du marché thérapeutique des polyneuropathies inflammatoires démyélinisantes inflammatoires chroniques. Par exemple, UCB S.A a initié des essais cliniques de phase 2 pour le Rozanolixizumab pour le traitement des patients atteints de polyneuropathie démyélinisante inflammatoire chronique. De plus, le soutien actif du gouvernement dans la sensibilisation aux maladies neurologiques rares ainsi que le lancement de candidats médicaments potentiels devraient contribuer à la croissance du marché thérapeutique mondial des polyneuropathies inflammatoires démyélinisantes chroniques. Par exemple, Pfizer Inc. a lancé l’étude clinique de phase 1 pour PF-06755347, un médicament candidat immunomodulateur recombinant pour le traitement de la polyneuropathie démyélinisante inflammatoire chronique. Néanmoins, le prix élevé des médicaments approuvés devrait restreindre les parts de marché mondiales des traitements de la polyneuropathie inflammatoire démyélinisante inflammatoire chronique. En outre, la présence d’options de traitement limitées devrait entraver la croissance du marché thérapeutique mondial des polyneuropathies inflammatoires démyélinisantes chroniques.

Request customization

www.fortunebusinessinsights.com/enquiry/customization/chronic-inflammatoire-demyelinating-polyneuropathy-therapeutics-market-100717